Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?

NEW YORK CITY, NY / ACCESSWIRE / October 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. ("Novavax" or "the Company") (NASDAQ:NVAX). Investors who purchased Novavax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NVAX.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novavax, Inc. (NVAX) And Encourages Investors to Reach Out

Let's look beyond this piece of bad news from regulators.

This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?

NEW YORK--(BUSINESS WIRE)---- $NVAX #Novavax--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or “the Company”) (NASDAQ: NVAX). Investors who purchased Novavax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NVAX. Investigation Details On October 16, 2024, Novavax issued a press release “announc[ing] that the U.S. Food and Drug Administr.

NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Novavax, Inc. and Encourages Investors to Contact the Firm

NEW YORK CITY, NY / ACCESSWIRE / October 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. ("Novavax" or "the Company") (NASDAQ:NVAX). Investors who purchased Novavax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NVAX.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Novavax, Inc. (NVAX) And Encourages Stockholders to Reach Out

Novavax stock fell 20% in one trading session on the news.

How Bad Is This News for Novavax?

Novavax (NVAX) closed at $10.35 in the latest trading session, marking a +1.97% move from the prior day.

Novavax (NVAX) Advances While Market Declines: Some Information for Investors

NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the combo shot reported nerve damage.

Novavax Stock Falls After FDA Puts Two Vaccine Programs on Hold

NEW YORK CITY, NY / ACCESSWIRE / October 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. ("Novavax" or "the Company") (NASDAQ:NVAX). Investors who purchased Novavax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NVAX.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Novavax, Inc. (NVAX) And Encourages Stockholders to Connect

Novavax, Inc. (NASDAQ:NVAX) shares plummeted on Wednesday on news it faced a clinical hold on its CIC flu combination vaccine program after a serious adverse event (SAE) was reported in a Phase 2 trial participant. The SAE, motor neuropathy, surfaced in September 2024, nearly two years after the individual received the vaccine in January 2023.

Novavax shares tumble after clinical hold on flu combo vaccine

GlaxoSmithKline

Moderna

Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring.

3 Vaccine Stocks to Watch as Flu Season Approaches

Novavax (NVAX) shares plummeted nearly 20% Wednesday after the Food and Drug Administration (FDA) stopped research on the biotech firm's experimental combination COVID-19 and flu vaccine and standalone flu shot following a report of nerve damage in one patient who took the combination injection.

Novavax Stock Plunges as FDA Puts Hold on Vaccines Because of Safety Concerns

Novavax said the Food and Drug Administration has put a hold on its application for a combination shot targeting Covid and influenza and a standalone flu vaccine, sending shares of the company down sharply.  The so-called clinical hold is due to a single report of nerve damage in a patient who received the combination shot in a phase two trial that finished in July last year.

Novavax says FDA put hold on combination Covid-flu shot and influenza vaccine; shares plunge

The regulator placed a clinical hold on its Covid-19-influenza combination vaccine after one person reported nerve damage.

Novavax Stock Tumbles 20% as FDA Pauses Clinical Trial on Security Concerns

Novavax Inc.'s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu vaccine candidates, following a case of motor neuropathy in a participant in a mid-stage trial.

Novavax's stock slides 16% after FDA puts clinical hold on COVID and flu vaccine candidates

GAITHERSBURG, Md. , Oct. 16, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates.

Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

The U.S. Food and Drug Administration has placed a hold on clinical trials of Novavax's COVID and influenza combination vaccine, as well as standalone flu shot after a serious side-effect was seen in a participant, the company said on Wednesday.

US FDA places trials of two Novavax vaccines on hold

The European Union authorized Novavax's updated COVID vaccine targeting the JN.1 strain of coronavirus, the company said on Wednesday.

EU authorizes Novavax's updated COVID vaccine targeting JN.1 strain

GAITHERSBURG, Md. , Oct. 9, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the European Commission granted Marketing Authorization for Novavax's updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for injection, for use in individuals aged 12 and older for the prevention of COVID-19 in the European Union (EU).

Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know

Shares of Novavax (NVAX, Financial), a biotechnology firm specializing in vaccine development, experienced a significant drop of 5.11%. The stock is currently priced at $12.92 with a trading volume of approximately 3.03 million shares, reflecting a turnover rate of 1.89% and a price fluctuation of 6.10%.

Novavax (NVAX) Stock Dips Amidst Volatility in Biotech Sector

Novavax (NVAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Novavax (NVAX) Moves 19.2% Higher: Will This Strength Last?

Ruxandra Draghia-Akli, MD, PhD brings more than 20 years of extensive clinical, corporate and global public health expertise to support Novavax's transition to an R&D-focused organization Dr. Draghia-Akli will be integral in strategically evaluating the Company's pipeline and opportunities for its Matrix-M™ adjuvant and protein-based technology platform GAITHERSBURG, Md. , Sept. 25, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Ruxandra Draghia-Akli, MD, PhD, will join the Company in November 2024 as Executive Vice President and Head of Research & Development (R&D).

Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

In the most recent trading session, Novavax (NVAX) closed at $12.80, indicating a -0.85% shift from the previous trading day.

Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade

Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back.

News for Novavax Stock (NVAX)